Literature DB >> 1752724

Effect of obesity on circulating intermediary metabolite concentrations in the absence of impaired glucose tolerance.

D A Robertson1, B M Singh, M Nattrass.   

Abstract

The published literature on the influence of obesity on intermediary metabolite concentrations does not adequately address the potential confounding effects of the increased prevalence of impaired glucose tolerance in obese subjects. In order to remove this, we studied 109 subjects with proven normal glucose tolerance ranging from underweight to grossly obese (range 15.3-80.9 body mass index). All had blood intermediary metabolites, plasma insulin and C-peptide measured after an overnight fast. Thirty-six (18 from each end of the range of body mass index) received a 3-hour oral glucose tolerance test for metabolites and insulin. Fasting plasma insulin was highly significantly associated with body mass index (r = 0.72; P less than 0.001). Concentrations of lipid intermediaries were better associated with body mass index than with fasting plasma insulin: non-esterified fatty acids (r = 0.36; P less than 0.001), glycerol (r = 0.47; P less than 0.001) and ketone bodies (r = 0.45; P less than 0.001). Fasting concentrations of carbohydrate intermediaries were, however, better correlated with fasting plasma insulin: lactate (r = 0.29; P less than 0.01), pyruvate (r = 0.24; P less than 0.01) and alanine (r = 0.36; P less than 0.001). Glucose concentrations were associated with both to a similar degree (r = 0.33, r = 0.32, respectively; P less than 0.001). After oral glucose, exaggerated rises in plasma insulin and blood glucose were observed in obese subjects but a lesser rise was seen for lactate. Non-esterified fatty acids and ketones, although having higher fasting concentrations in obese subjects, fell to similar concentrations in the two groups after glucose whereas blood glycerol did not fall so far in the obese subjects. The results suggest, even if those subjects with impaired glucose tolerance are excluded, insensitivity to insulin in several aspects of intermediary metabolism in obesity the degree of which may vary in different metabolic pathways or tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752724

Source DB:  PubMed          Journal:  Int J Obes


  7 in total

Review 1.  Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state.

Authors:  Sean H Adams
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

2.  Effect of maternal body mass index on cord blood erthropoietin concentrations.

Authors:  S Barak; F B Mimouni; R Stern; N Cohen; R Marom
Journal:  J Perinatol       Date:  2014-08-07       Impact factor: 2.521

3.  Adiponectin corrects high-fat diet-induced disturbances in muscle metabolomic profile and whole-body glucose homeostasis.

Authors:  Ying Liu; Subat Turdi; Taesik Park; Nicholas J Morris; Yves Deshaies; Aimin Xu; Gary Sweeney
Journal:  Diabetes       Date:  2012-12-13       Impact factor: 9.461

Review 4.  Metabolic complications of obesity.

Authors:  S M Grundy
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.925

5.  Plasma Lactate Levels Increase during Hyperinsulinemic Euglycemic Clamp and Oral Glucose Tolerance Test.

Authors:  Feven Berhane; Alemu Fite; Nour Daboul; Wissam Al-Janabi; Zaher Msallaty; Michael Caruso; Monique K Lewis; Zhengping Yi; Michael P Diamond; Abdul-Badi Abou-Samra; Berhane Seyoum
Journal:  J Diabetes Res       Date:  2015-04-19       Impact factor: 4.011

6.  Fatty Acids, Obesity and Insulin Resistance.

Authors:  Peter Arner; Mikael Rydén
Journal:  Obes Facts       Date:  2015       Impact factor: 3.942

7.  Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity.

Authors:  Oded Shaham; Ru Wei; Thomas J Wang; Catherine Ricciardi; Gregory D Lewis; Ramachandran S Vasan; Steven A Carr; Ravi Thadhani; Robert E Gerszten; Vamsi K Mootha
Journal:  Mol Syst Biol       Date:  2008-08-05       Impact factor: 11.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.